Browse > Article
http://dx.doi.org/10.3904/kjim.2012.27.4.436

The Progression of Bone Mineral Density Loss in Dialysis Patients Compared with the General Population  

Avramovski, Petar (Department of Internal Medicine and Hemodialysis, Clinical Hospital)
Sikole, Aleksandar (Department of Nephrology, Ss. Cyril and Methodius University of Skopje Faculty of Medicine)
Publication Information
The Korean journal of internal medicine / v.27, no.4, 2012 , pp. 436-442 More about this Journal
Abstract
Background/Aims: The aim of this study was to compare the progression of bone mass loss in chronic hemodialysis patients (CHPs) with that in general population patients (GPPs) over an 18-month period. Methods: The control group consisted of 60 patients (aged $57.5{\pm}10.9$ years) with a glomerular filtration rate > $60mL/min/1.73m^2$. The study group included 80 patients undergoing hemodialysis (aged $59.3{\pm}11.8$ years; duration of dialysis $5.47{\pm}5.16$ years). Bone mineral density (BMD) testing was conducted in both groups using dual energy X-ray absorptiometry at hip and lumbar spine regions at baseline and after 18 months. Biochemical parameters (albumin, C-reactive protein, calcium, ionized calcium, alkaline phosphatase, and parathyroid hormone) were determined in all participants using standard laboratory procedures. Results: The mean values of BMD (average hip + lumbar spine) were $0.900{\pm}0.14g/cm^2$ and $0.866{\pm}0.14g/cm^2$ in the GPP and $0.823{\pm}0.16g/cm^2$ and $0.769{\pm}0.13g/cm^2$ in the CHP groups at baseline and 18 months, respectively. The statistical significance (p value) of hip bone loss progression over 18 months was 0.0577 for GPP and 0.0002 for CHP, whereas that of lumbar spine bone loss progression was 0.6820 for GPP and 0.5389 for CHP. Conclusions: The of progression bone mass loss was significantly greater in CHP than in GPP. Bone mass loss was evident even over 1 month, albeit in only the CHP with accelerated osteoporosis.
Keywords
Osteoporosis; Bone density; Renal dialysis; Femoral neck; Lumbar vertebrae;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Lindberg JS, Moe SM. Osteoporosis in end-state renal disease. Semin Nephrol 1999;19:115-122.
2 Gal-Moscovici A, Sprague SM. Osteoporosis and chronic kidney disease. Semin Dial 2007;20:423-430.   DOI   ScienceOn
3 Cunningham J, Sprague SM, Cannata-Andia J, et al. Osteoporosis in chronic kidney disease. Am J Kidney Dis 2004;43:566-571.   DOI   ScienceOn
4 Lewiecki EM, Binkley N, Petak SM. DXA quality matters. J Clin Densitom 2006;9:388-392.   DOI   ScienceOn
5 El Maghraoui A, Roux C. DXA scanning in clinical practice. QJM 2008;101:605-617.   DOI   ScienceOn
6 Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 2008;23:586-593.
7 Adler RA. Osteoporosis: Pathophysiology and Clinical Management. 2nd ed. Totowa: Humana Press, 2010.
8 D'Erasmo E, Pisani D, Ragno A, Raejntroph N, Letizia C, Acca M. Relationship between serum albumin and bone mineral density in postmenopausal women and in patients with hypoalbuminemia. Horm Metab Res 1999;31:385-388.   DOI
9 Kaysen GA. Serum albumin concentration in dialysis patients: why does it remain resistant to therapy? Kidney Int Suppl 2003:S92-S98.
10 Taal MW, Masud T, Green D, Cassidy MJ. Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant 1999;14:1922-1928.   DOI   ScienceOn
11 Gabay C, Ruedin P, Slosman D, Bonjour JP, Leski M, Rizzoli R. Bone mineral density in patients with end-stage renal failure. Am J Nephrol 1993;13:115-123.   DOI   ScienceOn